Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial
The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, phase 2a, randomized, double-blind, PBO-controlled, multicenter, parallel-group study enrolled individuals who were obese or overweight without type 2 diabetes (N = 335, aged 18–65 years, BMI ≥30 to <50 kg/m2 or BMI ≥27 to <50 kg/m2 with hypertension and/or dyslipidemia). Participants were randomized (1:1:1:1) to receive PBO, CANA 300 mg, PHEN 15 mg, or coadministration of CANA 300 mg and PHEN 15 mg (CANA/PHEN) orally once daily. The primary end point was percent change in body weight from baseline to week 26; key secondary end points were the proportion of participants achieving weight loss ≥5% and change from baseline in systolic blood pressure. RESULTS: CANA/PHEN provided statistically superior weight loss from baseline versus PBO at week 26 (least squares mean difference –6.9% [95% CI –8.6 to –5.2]; P < 0.001). CANA/PHEN also provided statistically superior achievement of weight loss ≥5% and reduction in systolic blood pressure compared with PBO. CANA/PHEN was generally well tolerated, with a safety and tolerability profile consistent with that of the individual components. CONCLUSIONS: CANA/PHEN produced meaningful reductions in body weight and was generally well tolerated in individuals who were overweight or obese without type 2 diabetes. Further studies are warranted to evaluate potential use of this combination for long-term weight management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Canagliflozin/phentermine had statistically superior percent weight loss versus placebo (difference of e6.9%; P < .001)(Hollander et al, 2017).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Hollander et al, 2017
In the citing paper
“Canagliflozin/phentermine was generally well tolerated, with a safety profile consistent with that of each drug alone (Appendix 3) (Hollander et al, 2017).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Hollander et al, 2017
In the citing paper
“The M. Kokkorakis, M. Chakhtoura, C. Rhayem et al. Pharmacological Reviews 77 (2025) 100002 least-square means percent changes in body weight were e1.9 (SE 0.6) with canagliflozin, e4.1 (SE 0.6) with phentermine, and e7.5 (SE 0.6) with canagliflozin/phentermine, and e0.6 (SE 0.6) with placebo (Fig. 4) (Hollander et al, 2017).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Hollander et al, 2017
In the citing paper
“In a nod to this idea, current antiobesity medications in the pipeline include dual agonist and triple agonist agents, drugs that simultaneously target multiple pathways (eg, tirzepatide, which targets GLP-1 receptor agonist and GIP receptor agonist) 43 in an attempt to circumvent these natural redundancies.149 -152”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [150]
In the citing paper
“From the perspective of prospective controlled clinical trials, the placebo-corrected phentermine weight reduction is about 3–8%”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [37]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Quantification of the effect of energy imbalance on bodyweight
Hall, K. D., Sacks, G., Chandramohan, D., Chow, C. C., Wang, Y. C., Gortmaker, S. L., & Swinburn, B. A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60812-x · Cited by 1,165
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Research works printed but not linked: 1
- Toubro, 2012, Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes, Diabetologia, 55, S313
Cited by
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Emerging role of SGLT-2 inhibitors for the treatment of obesity
Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342
Medications for Obesity: A Review
Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Brown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
Lee, P. C., Ganguly, S., & Goh, S. ‐. (2018) · Obesity Reviews · doi:10.1111/obr.12755 · Cited by 189
“6% in those on canagliflozin alone (61).”
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Tak, Y. J., & Lee, S. Y. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200010 · Cited by 184
Yang, X., Liu, Q., Li, Y., Tang, Q., Wu, T., Chen, L., Pu, S., Zhao, Y., Zhang, G., Huang, C., et al. (2020) · Adipocyte · doi:10.1080/21623945.2020.1807850 · Cited by 172
Saunders, K. H., Umashanker, D., Igel, L. I., Kumar, R. B., & Aronne, L. J. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.010 · Cited by 159
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A., Koliaki, C. C., & Mantzoros, C. S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 128
Teo, Y. H., Teo, Y. N., Syn, N. L., Kow, C. S., Yoong, C. S. Y., Tan, B. Y. Q., Yeo, T., Lee, C., Lin, W., & Sia, C. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019463 · Cited by 140
Pediatric obesity: Current concepts
Greydanus, D. E., Agana, M. G., Kamboj, M. K., Shebrain, S., Soares, N. S., Eke, R., & Patel, D. R. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2017.12.001 · Cited by 128
Applications of SGLT2 inhibitors beyond glycaemic control
O’Hara, D. V., Lam, C. S. P., McMurray, J. J. V., Yi, T. W., HOCKING, S. L., Dawson, J., Raichand, S., Januszewski, A. S., & Jardine, M. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00836-y · Cited by 128
Horn, D. B., Almandoz, J. P., & Look, M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2051366 · Cited by 114
“However, while combination treatment with AOMs that have different modes of actions may be beneficial for some individuals, few randomized trials have shown the efficacy of combining different AOMs or combining AOMs with other medications for weight loss and disease improvement [51,52].”
BackgroundEmerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
Ryder, J. R., Fox, C. K., & Kelly, A. S. (2018) · Obesity · doi:10.1002/oby.22196 · Cited by 83
SGLT2 inhibitors: Beyond glycemic control
Hasan, I., Rashid, T., Jaikaransingh, V., Heilig, C., Abdel‐Rahman, E. M., & Awad, A. S. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100335 · Cited by 89
Off-label drugs for weight management
Hendricks, E. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s95299 · Cited by 82
“A recent report of a trial combining canagliflozen and phentermine for overweight patients without diabetes suggests this off-label combination can induce weight loss superior to diet and lifestyle modification without these medications.(45)”
Revised definition of obesity in Asian Indians living in India
Misra, A., Vikram, N. K., Ghosh, A., Ranjan, P., & Gulati, S. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102989 · Cited by 75
Zhang, J., Xing, C., Cheng, X., & He, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1003238 · Cited by 73
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Self-citationEffectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Busch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 57
Differential mechanisms affecting weight loss and weight loss maintenance
Rosenbaum, M., & Foster, G. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00864-1 · Cited by 61
Zheng, H., Liu, M., Li, S., Shi, Q., Zhang, S., Zhou, Y., & Su, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.706914 · Cited by 60
“The adverse events included general adverse events and serious adverse events; (4) Study design: randomized controlled trials (RCTs) limited to the English language without restrictions of study size, follow-up length or publication year.”
BackgroundInfluentialObesity Pharmacotherapy in Patients With Type 2 Diabetes
Kahan, S., & Fujioka, K. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0044 · Cited by 50
Weight-centric treatment of type 2 diabetes mellitus
Ghusn, W., Hurtado, M. D., & Acosta, A. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100045 · Cited by 40
Ali, A. M., Martinez, R., Al-Jobori, H., Adams, J., Triplitt, C., DeFronzo, R., Cersosimo, E., & Abdul-Ghani, M. (2020) · Diabetes Care · doi:10.2337/dc18-2460 · Cited by 46
Cho, Y. K., Kim, Y., & Jung, C. H. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21061 · Cited by 47
Pratama, K. G., Tandarto, K., & Hengky, A. (2022) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2022.216 · Cited by 46
Obesidad y diabetes mellitus tipo 2: también unidas en opciones terapéuticas
Rubio-Almanza, M., Cámara-Gómez, R., & Merino-Torres, J. F. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.003 · Cited by 46
Zhou, Y., Suo, W., Zhang, X., Liang, J., Zhao, W., Wang, Y., Li, H., & Ni, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115669 · Cited by 44
Combination therapy for obesity
Wilding, J. P. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117737401 · Cited by 37
Obesity an overview: Genetic conditions and recent developments in therapeutic interventions
Rao, V., Candasamy, M., & Bhattamisra, S. K. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.004 · Cited by 39
The role of SGLT-2 inhibitors in managing type 2 diabetes
Tsushima, Y., Lansang, M. C., & Makin, V. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20088 · Cited by 37
SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure
Gupta, R., Maitz, T., Egeler, D., Mehta, A., Nyaeme, M. S., Hajra, A., Goel, A., Sreenivasan, J., Patel, N., & Aronow, W. S. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.05.005 · Cited by 37
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
Obesity and type 2 diabetes: Also linked in therapeutic options
Rubio-Almanza, M., Cámara-Gómez, R., & Merino-Torres, J. F. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.11.006 · Cited by 34
Treating the Chronic Disease of Obesity
Gossmann, M., Butsch, W. S., & Jastreboff, A. M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.005 · Cited by 33
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 33
SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells
Anastasio, C., Donisi, I., Vecchio, V. D., Colloca, A., Mele, L. L., Sardu, C., Marfella, R., Balestrieri, M. L., & D’Onofrio, N. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00599-1 · Cited by 33
Pereira, M. J., Lundkvist, P., Kamble, P. G., Lau, J., Martins, J. G., Sjöström, C. D., Schnecke, V., Walentinsson, A., JOHNSSON, E. K., & Eriksson, J. W. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0449-6 · Cited by 32
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 26
Bapir, R., Bhatti, K. H., Eliwa, A., García‐Perdomo, H. A., Gherabi, N., Hennessey, D. B., Magri, V., Mourmouris, P., Ouattara, A., Perletti, G., et al. (2023) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2023.11509 · Cited by 25
Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
Kalra, S., Shetty, K., Nagarajan, V. B., & Ved, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00789-y · Cited by 22
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 22
Obesity pillars roundtable: Phentermine – Past, present, and future
Bays, H. E., Lazarus, E., Primack, C., & Fitch, A. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100024 · Cited by 22
Self-citationHeymsfield, S. B., Raji, A., Gallo, S., Liu, J., Pong, A., Hannachi, H., & Terra, S. G. (2020) · Obesity · doi:10.1002/oby.22748 · Cited by 21
A review of the evidence on cardiovascular outcomes from obesity treatment
Wahab, R. A., & le Roux, C. W. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100071 · Cited by 21
Wong, J., Chan, K. Y., & Lo, K. K.-H. (2021) · Obesity Reviews · doi:10.1111/obr.13336 · Cited by 21
Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis
Do, A., Kuszewski, E. J., Langberg, K. A., & Mehal, W. Z. (2019) · Hepatology · doi:10.1002/hep.30658 · Cited by 20
Zheng, W., Qi, Q., Li, J., He, C., & Fan, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01917-z · Cited by 19
Bays, H. E., Burridge, K., Richards, J., & Fitch, A. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100039 · Cited by 18
Self-citationTeo, Y. H., Chia, A. Z. Q., Teo, Y. N., Chong, E. Y., Syn, N. L. X., Cheong, J. Y. A., Ong, H. T., Wee, C. F., Ting, A. Z. H., Tan, J. T. A., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003280 · Cited by 18
Ramirez, A. V. G., Filho, D. R., & Filho, I. J. Z. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666191113125247 · Cited by 16
Khiali, S., Sadeghi, M. T., Sarbakhsh, P., Khezerlouy‐Aghdam, N., Rezagholizadeh, A., Asham, H., & Entezari‐Maleki, T. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2311 · Cited by 15
Luo, S., Lenon, G. B., Gill, H. S., Yuen, H., Yang, A. W. H., Hung, A., & Nguyen, L. T. (2018) · Current Drug Targets · doi:10.2174/1389450119666180830125958 · Cited by 14
Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients
dos Santos, L. R., & Filho, R. B. (2020) · Metabolism Open · doi:10.1016/j.metop.2020.100028 · Cited by 14
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Giovanni, C. B. S., Sweeney, B. R., Skelton, J. A., Kelsey, M. M., & Kelly, A. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab276 · Cited by 13
The Effective Use of Anti-obesity Medications
Schmitz, S. H., & Aronne, L. J. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.003 · Cited by 13
Influence of modern antidiabetic therapy on body weight in patients with type 2 diabetes mellitus
Салухов, В. В., Ilyinskaya, Т. A., & Minakov, A. A. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-1-39-52 · Cited by 13
Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice
Yildirim, G., Bergamo, E. T. P., Poudel, S. B., Ruff, R. R., Dixit, M., Hu, B., Mijares, D. Q., Witek, L., Chlebek, C., Harrison, D. E., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00803-8 · Cited by 12
Management of Hypertension in Diabetic Kidney Disease
Colbert, G. B., Elrggal, M. E., Gaddy, A. R., Madariaga, H. M., & Lerma, E. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216868 · Cited by 12
The Emerging Role of Injectable Weight Loss Medications in Plastic Surgery: A Systematic Review
Shridharani, S. M., & Kohan, J. (2023) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad240 · Cited by 12
Farmakoterapia otyłości — obecny stan wiedzy
Matyjaszek‐Matuszek, B., Szafraniec, A., & Porada, D. (2018) · Endokrynologia Polska · doi:10.5603/ep.2018.0048 · Cited by 13
Shi, Y., Si, Y., Fu, R., Zhang, M., Jiang, K., Dai, W., Shen, J., Li, X., & Yuan, Y. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2021.0102 · Cited by 11
Gliflozins in hypertension: basic mechanisms and clinical insights
Rieg, T., Liu, R., & Staruschenko, A. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00119.2025 · Cited by 10
Inan, F., Brunt, T. M., Contrucci, R. R., Hondebrink, L., & Franssen, E. J. F. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000725 · Cited by 10
An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Wu, P., Liu, Z., Jiang, X., & Fang, H. (2019) · Current Drug Targets · doi:10.2174/1389450120666191031104653 · Cited by 9
Weight loss to disrupt type 2 diabetes
Alsaqaaby, M. S., & le Roux, C. W. (2023) · Diabetology International · doi:10.1007/s13340-023-00626-0 · Cited by 8
Abiri, B., Ahmadi, A. R., Ebadinejad, A., Hosseinpanah, F., & Valizadeh, M. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2115775 · Cited by 7
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
Evans, M., Morgan, A. R., Yousef, Z. R., Ellis, G., Dashora, U. K., Patel, D., Brown, P., Hanif, W., Townend, J. N., Kanumilli, N., et al. (2021) · Drugs · doi:10.1007/s40265-021-01538-6 · Cited by 7
Li, F., Baheti, R., Jin, M., Xiong, W., Duan, J., Peng, F., & Wan, J. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01553-z · Cited by 5
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
Kugathasan, L., Dubrofsky, L., Advani, A., & Cherney, D. Z. I. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2159810 · Cited by 5
Obesity Pharmacotherapy: a Review of Current Practices and Future Directions
Schmitz, S. H., Tchang, B. G., & Shukla, A. P. (2023) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-023-00409-1 · Cited by 5
Lee, C. J., Kim, M.-J., & An, S. J. (2019) · Daehan imsang geon-gang jeungjin hakoeji/Daehan imsang geon'gang jeungjin haghoeji · doi:10.15384/kjhp.2019.19.4.171 · Cited by 5
Zhao, S., Zhou, L., Tao, Y., Yue, Y., Wang, J., Shen, L., Lu, G., & Hang, Y. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00999-5 · Cited by 5
Modulation of Glucagon Signaling
Pocai, A. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.03.006 · Cited by 5
Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity
Gorain, B., Choudhury, H., Sengupta, P., Verma, R. K., & Pandey, M. (2021) · Springer eBooks · doi:10.1007/978-981-33-6408-0_10 · Cited by 4
Hejazi, M. M., Bacha, A. O., Mohammed, K., Al-Abbasi, F. A., Al-Alsieni, A. I., Kazmi, I. A., & Anwar, F. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3255-y · Cited by 4
Promising areas of pharmacotherapy for obesity
Druzhilov, M., Kuznetsova, T., & Chumakova, G. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4279 · Cited by 4
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
Abiri, B., Ahmadi, A. R., Hosseinpanah, F., Valizadeh, A., Zarghi, A., & Valizadeh, M. (2024) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-024-01692-2 · Cited by 3
SGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review
Sousa, M., Almeida, C., Marchão, N., Godinho, I., Lopes, J. A., & Gameiro, J. (2023) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2023.03.234 · Cited by 3
Krentz, A. J., & Rodriguez‐Araujo, G. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0209-3 · Cited by 3
Medical Management of Obesity as it Affects Reflux
Haddad, J. D., & Shah, S. L. (2021) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161211069183 · Cited by 3
Una visión actual del tratamiento farmacológico para la obesidad
Ferran, M. C. D. L. P. A. F. P. M. R., Pérez, A. F., & Ferran, M. R. (2022) · Rovira & Virgili repository · Cited by 3
Pharmacological Strategies for Pediatric Obesity
Fox, C. K., Raatz, S. J., & Sweeney, B. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-37380-0_6 · Cited by 2
Reflections on the concept of optimality of single decision point treatment regimes
Tran, T. D., Alonso, A., Verbeke, G. N., Molenberghs, G., & Mechelen, I. V. (2023) · Biometrical Journal · doi:10.1002/bimj.202200285 · Cited by 2
Rubio-Almanza, M. (2019) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14103.2019.664939 · Cited by 2
Role of SGLT2 inhibitors in the treatment of visceral obesity
Druzhilov, М. A., & Kuznetsova, Т. Y. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2648 · Cited by 1
Methods of treatment of obesity in patients with type 2 diabetes
Pasek, I., Wiska, L., Kopytko, P., & Banach, B. (2021) · Farmacja Polska · doi:10.32383/farmpol/142112 · Cited by 1
Adjunctive Therapy, Including Pharmacotherapy
Al-Bazz, D. Y., & Wilding, J. P. H. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch21 · Cited by 1
Elrggal, M. E., Elkeraie, A. F., Carriazo, S. M., Sawaf, H., Khor, S. Y., Elkeraie, Y., Haddad, I. R., Moustafa, K., & Hassanein, M. M. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070009 · Cited by 1
Metadata
- Authors
- Hollander, P., Bays, H. E., Rosenstock, J., Frustaci, M. E., Fung, A., Vercruysse, F., & Erondu, N.
- Affiliations
- Baylor University Medical Center (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Dallas Diabetes Research Center (US)
- Janssen Research & Development, LLC, Spring House, PA
- Janssen Research & Development (United States) (US)
- Janssen (Belgium) (BE)
- Corresponding author
- Hollander, Priscilla
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-03-13
- Volume
- 40
- Issue
- 5
- Pages
- 632-639
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2595578651
- Cited by
- 106
- References
- 30
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 9 · 2023: 17 · 2022: 16 · 2021: 18 · 2020: 10 · 2019: 8 · 2018: 10 · 2017: 8
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- canagliflozin, phentermine, combination therapy, weight loss, obesity, overweight, non-diabetic obesity, SGLT2 inhibitors, appetite suppressants, systolic blood pressure, hypertension, dyslipidemia, drug safety and tolerability
- MeSH terms
- Canagliflozin, Adult, Appetite Depressants, Blood Pressure, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Phentermine, Thiophenes, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.